BiotechTube

TQJ230 + Placebo

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Conditions

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Trial Timeline

Apr 24, 2024 → Mar 31, 2026

NCT ID
NCT06267560

About TQJ230 + Placebo

TQJ230 + Placebo is a phase 3 stage product being developed by Novartis for Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06267560. Target conditions include Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease.

What happened to similar drugs?

0 of 3 similar drugs in Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease were approved

Approved (0) Terminated (2) Active (1)
🔄Muvalaplin + PlaceboEli LillyPhase 3
❌RosuvastatinAstraZenecaPhase 3
❌IvabradineAmgenPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06267560Phase 3Active
NCT04023552Phase 3Active

Competing Products

12 competing products in Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

See all competitors
ProductCompanyStageHype Score
Muvalaplin + PlaceboEli LillyPhase 3
47
BaricitinibEli LillyPre-clinical
26
RosuvastatinAstraZenecaPhase 3
32
LIK066 + PlaceboNovartisPhase 2
35
OlpasiranAmgenPhase 1
29
Maridebart cafraglutide + PlaceboAmgenPhase 2
42
IvabradineAmgenPhase 3
32
ALN-PCS02 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
ISIS-APO(a)Rx + PlaceboIonis PharmaceuticalsPhase 2
32
APOC-III-L-Rx + Placebo ComparatorIonis PharmaceuticalsPhase 1
26
ISIS 681257 + PlaceboIonis PharmaceuticalsPhase 2
32
IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl)Ionis PharmaceuticalsPhase 1
26